Tags

Type your tag names separated by a space and hit enter

Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients.
. 2005 Jun 01; 39(2):167-73.

Abstract

Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine. From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%-10%] in vaccinated vs. 21.2% [CI: 13%-35%] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count >200 cells/muL compared with those with a CD4 count <200 cells/muL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.

Authors+Show Affiliations

AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15905732

Citation

Yamanaka, Hikaru, et al. "Efficacy and Immunologic Responses to Influenza Vaccine in HIV-1-infected Patients." Journal of Acquired Immune Deficiency Syndromes (1999), vol. 39, no. 2, 2005, pp. 167-73.
Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(2):167-73.
Yamanaka, H., Teruya, K., Tanaka, M., Kikuchi, Y., Takahashi, T., Kimura, S., & Oka, S. (2005). Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999), 39(2), 167-73.
Yamanaka H, et al. Efficacy and Immunologic Responses to Influenza Vaccine in HIV-1-infected Patients. J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):167-73. PubMed PMID: 15905732.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. AU - Yamanaka,Hikaru, AU - Teruya,Katsuji, AU - Tanaka,Mari, AU - Kikuchi,Yoshimi, AU - Takahashi,Takao, AU - Kimura,Satoshi, AU - Oka,Shinichi, AU - ,, PY - 2005/5/21/pubmed PY - 2005/9/27/medline PY - 2005/5/21/entrez SP - 167 EP - 73 JF - Journal of acquired immune deficiency syndromes (1999) JO - J. Acquir. Immune Defic. Syndr. VL - 39 IS - 2 N2 - Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine. From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%-10%] in vaccinated vs. 21.2% [CI: 13%-35%] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count >200 cells/muL compared with those with a CD4 count <200 cells/muL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine. SN - 1525-4135 UR - https://www.unboundmedicine.com/medline/citation/15905732/Efficacy_and_immunologic_responses_to_influenza_vaccine_in_HIV_1_infected_patients_ L2 - https://Insights.ovid.com/pubmed?pmid=15905732 DB - PRIME DP - Unbound Medicine ER -